Intracranial hemorrhage after recombinant tissue plasminogen Activator: The competing risks survival analysis

Intravenous recombination of tissue plasminogen activator is a recommended treatment for patients with ischemic stroke. However, its side effects are associated with an increased risk of intracerebral hemorrhage. This study aimed to verify the factors associated with hemorrhagic transformation, clas...

Full description

Bibliographic Details
Main Authors: Waitayaporn Pengtong, Natnaree Aimyong, Yongchai Nilanont
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Interdisciplinary Neurosurgery
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2214751923000178
_version_ 1797867401898885120
author Waitayaporn Pengtong
Natnaree Aimyong
Yongchai Nilanont
author_facet Waitayaporn Pengtong
Natnaree Aimyong
Yongchai Nilanont
author_sort Waitayaporn Pengtong
collection DOAJ
description Intravenous recombination of tissue plasminogen activator is a recommended treatment for patients with ischemic stroke. However, its side effects are associated with an increased risk of intracerebral hemorrhage. This study aimed to verify the factors associated with hemorrhagic transformation, classified by the clinical system, with time from onset to treatment. The medical records of patients with ischemic stroke who underwent recombination tissue plasminogen activator therapy at Siriraj Hospital, Thailand from October 2005 to June 2017 were included in this study. A sub-distribution hazard function by Fine-Gray model was applied to the data. Of the 241 records, 12.9 % presented with intracerebral hemorrhage, 4.6 % were symptomatic, and 8.3% were asymptomatic. The factors associated with increased risks of symptomatic intracerebral hemorrhage were older age (6.38–7.62 times higher than that compared with patients of younger age), high initial blood glucose (14.5 times higher), and systolic blood pressure (7.84 times higher). The factors associated with the asymptomatic type, in comparison with the risk of the symptomatic type, were older age (1.67–9.46 times higher than that compared with patients of younger stroke), higher stroke severity (1.39 times higher), and history of aspirin use (1.79 times higher). Modern technology and medical innovations cannot change the factors affecting intracranial hemorrhage. Screening methods for identifying hemorrhagic transformation after recombinant tissue plasminogen activator are important for patients with ischemic stroke.
first_indexed 2024-04-09T23:39:36Z
format Article
id doaj.art-9380b0883bb74a11aa1354fd34b78f7f
institution Directory Open Access Journal
issn 2214-7519
language English
last_indexed 2024-04-09T23:39:36Z
publishDate 2023-06-01
publisher Elsevier
record_format Article
series Interdisciplinary Neurosurgery
spelling doaj.art-9380b0883bb74a11aa1354fd34b78f7f2023-03-19T04:37:53ZengElsevierInterdisciplinary Neurosurgery2214-75192023-06-0132101734Intracranial hemorrhage after recombinant tissue plasminogen Activator: The competing risks survival analysisWaitayaporn Pengtong0Natnaree Aimyong1Yongchai Nilanont2Faculty of Public Health, and Faculty of Medicine, Siriraj Hospital, Mahidol University, ThailandFaculty of Public Health, Mahidol University, Thailand; Corresponding author at: 420/1 Ratchawithi, Rd., Ratchathewi, Bangkok 10400, Thailand.Faculty of Medicine, Siriraj Hospital, Mahidol University, ThailandIntravenous recombination of tissue plasminogen activator is a recommended treatment for patients with ischemic stroke. However, its side effects are associated with an increased risk of intracerebral hemorrhage. This study aimed to verify the factors associated with hemorrhagic transformation, classified by the clinical system, with time from onset to treatment. The medical records of patients with ischemic stroke who underwent recombination tissue plasminogen activator therapy at Siriraj Hospital, Thailand from October 2005 to June 2017 were included in this study. A sub-distribution hazard function by Fine-Gray model was applied to the data. Of the 241 records, 12.9 % presented with intracerebral hemorrhage, 4.6 % were symptomatic, and 8.3% were asymptomatic. The factors associated with increased risks of symptomatic intracerebral hemorrhage were older age (6.38–7.62 times higher than that compared with patients of younger age), high initial blood glucose (14.5 times higher), and systolic blood pressure (7.84 times higher). The factors associated with the asymptomatic type, in comparison with the risk of the symptomatic type, were older age (1.67–9.46 times higher than that compared with patients of younger stroke), higher stroke severity (1.39 times higher), and history of aspirin use (1.79 times higher). Modern technology and medical innovations cannot change the factors affecting intracranial hemorrhage. Screening methods for identifying hemorrhagic transformation after recombinant tissue plasminogen activator are important for patients with ischemic stroke.http://www.sciencedirect.com/science/article/pii/S2214751923000178Acute ischemic strokeCompeting risks analysisIntracerebral hemorrhageTissue plasminogen activator
spellingShingle Waitayaporn Pengtong
Natnaree Aimyong
Yongchai Nilanont
Intracranial hemorrhage after recombinant tissue plasminogen Activator: The competing risks survival analysis
Interdisciplinary Neurosurgery
Acute ischemic stroke
Competing risks analysis
Intracerebral hemorrhage
Tissue plasminogen activator
title Intracranial hemorrhage after recombinant tissue plasminogen Activator: The competing risks survival analysis
title_full Intracranial hemorrhage after recombinant tissue plasminogen Activator: The competing risks survival analysis
title_fullStr Intracranial hemorrhage after recombinant tissue plasminogen Activator: The competing risks survival analysis
title_full_unstemmed Intracranial hemorrhage after recombinant tissue plasminogen Activator: The competing risks survival analysis
title_short Intracranial hemorrhage after recombinant tissue plasminogen Activator: The competing risks survival analysis
title_sort intracranial hemorrhage after recombinant tissue plasminogen activator the competing risks survival analysis
topic Acute ischemic stroke
Competing risks analysis
Intracerebral hemorrhage
Tissue plasminogen activator
url http://www.sciencedirect.com/science/article/pii/S2214751923000178
work_keys_str_mv AT waitayapornpengtong intracranialhemorrhageafterrecombinanttissueplasminogenactivatorthecompetingriskssurvivalanalysis
AT natnareeaimyong intracranialhemorrhageafterrecombinanttissueplasminogenactivatorthecompetingriskssurvivalanalysis
AT yongchainilanont intracranialhemorrhageafterrecombinanttissueplasminogenactivatorthecompetingriskssurvivalanalysis